Microvast Reports Second Quarter 2026 Financial Results
“In the second quarter,
Q2 2026 Results
- Revenues of
$87.3 million , compared to$91.3 million in Q2 2025, decreasing by$4.1 million , or 4.5%. This decrease was primarily driven by$2.7 million in IEEPA(1) tariff refunds issued to aU.S . customer, recorded as a reduction to revenue in the current period.
- Gross margin decreased to 29.5% from 34.7% in Q2 2025. Non-GAAP adjusted gross margin* decreased to 29.6% from 34.8% in Q2 2025, primarily due to higher raw material prices, and lower production utilization, which reduced fixed cost absorption, slightly offset by recognition of the IEEPA(1) tariff refunds received.
- Operating expenses increased to
$27.5 million , compared to$23.7 million in Q2 2025. Non-GAAP adjusted operating expenses* were$26.7 million , compared to$22.9 million in Q2 2025.
- Net loss of
$12.0 million , compared to net loss of$106.1 million in Q2 2025, primarily due to a reduction in negative impacts from changes in fair value of warrant liability and convertible loan. Non-GAAP adjusted net loss* was$5.3 million , compared to non-GAAP adjusted net profit* of$16.3 million in Q2 2025.
- Net loss per share of
$0.03 , compared to net loss per share of$0.33 in Q2 2025. Non-GAAP adjusted net loss per share* was$0.01 , compared to non-GAAP adjusted net profit per share* of$0.05 in Q2 2025.
- Non-GAAP adjusted EBITDA* of
$3.6 million in Q2 2026, compared to non-GAAP adjusted EBITDA* of$25.9 million in Q2 2025.
- Capital expenditures of
$11.3 million , compared to$7.4 million in Q2 2025.
- Cash, cash equivalents and restricted cash of
$143.1 million as ofJune 30, 2026 , compared to$169.2 million as ofDecember 31, 2025 , and$138.8 million as ofJune 30, 2025 .
Six Months Ended
- Revenues of
$147.9 million compared to$207.8 million in the six months endedJune 30, 2025 (“YTD 2025”), a decrease of 28.8%. This decrease was primarily a result of evolving regulatory and geopolitical dynamics, including in the Indian and Korean markets, demand shift towards lower-cost products inIndia , OEM platform ramp-up delays, and a$2.7 million IEEPA(1) tariff refund issued to a customer recorded as a reduction to our revenue in the current period.
- Gross margin decreased to 30.4% from 36.0% in YTD 2025. Non-GAAP adjusted gross margin* decreased to 30.4% from 36.0% in YTD 2025, primarily due to higher raw material prices, lower production utilization, which reduced fixed cost absorption, slightly offset by recognition of the IEEPA(1) tariff refunds received.
- Operating expenses increased to
$54.6 million , compared to$52.9 million in YTD 2025. Non-GAAP adjusted operating expenses* were$52.8 million , compared to$51.4 million in YTD 2025.
- Net profit of
$36.2 million , compared to net loss of$44.3 million in YTD 2025, primarily due to a reduction in negative impacts from changes in fair value of warrant liability and convertible loan. Non-GAAP adjusted net loss* was$19.9 million , compared to non-GAAP adjusted net profit of$35.6 million in YTD 2025.
- Net profit per share of
$0.11 , compared to net loss per share of$0.14 in YTD 2025. Non-GAAP adjusted net loss per share* was$0.06 , compared to non-GAAP adjusted net profit per share* of$0.11 in YTD 2025.
- Non-GAAP adjusted EBITDA* of negative
$1.9 million in YTD 2026, compared to non-GAAP adjusted EBITDA* of$54.4 million in YTD 2025.
- Capital expenditures of
$15.5 million , compared to$14.0 million in YTD 2025.
*The Company presents its financial results in accordance with generally accepted accounting principles in
(1)In
2026 Outlook & Forward-Looking Information
- We continue to target a stable gross margin profile through sustained operational discipline and premium product positioning. This approach seeks to balance external pressures including inflationary raw material pricing, duties and tariffs, and elevated logistics and freight expenses against the planned absorption of ramp-up expenses tied to our Phase 3.2 expansion.
- Huzhou Phase 3.2 production capacity ramp up remains our primary operational milestone in 2026. The expansion is anticipated to bring online up to 2 GWh of modular capacity to support next-generation cell demand.
- Localized pack assembly at our
Clarksville facility remains on schedule, with initial operations anticipated by year-end. This footprint advances our domestic strategy to supply North American commercial vehicle and transit partners with locally integrated battery systems. - We continue to seek new commercial momentum across EMEA,
North America , and APAC. Our long-term focus remains centered on heavy industrial and transit markets, where our vertical integration and newly launched KAF electric powertrain position us to deliver a durable competitive advantage, subject to final product validation, vehicle-level integration with OEM partners, customer qualification, and availability of domestic manufacturing capacity and capital.
Webcast Information
Company management will host a conference call and webcast on
About
For more information, please visit www.microvast.com or follow us on LinkedIn (@microvast).
Contact:
Investor Relations
ir@microvast.com
Cautionary Statement Regarding Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on assumptions with respect to the future and management's current expectations, involve certain risks and uncertainties and are not guarantees. These forward-looking statements include, but are not limited to, statements about our future results of operations and financial position, our operational performance, our anticipated growth and business strategy, anticipated development, commercialization, and market adoption of
Many factors could cause actual results and the timing of events to differ materially from the anticipated results or other expectations expressed in the forward-looking statements, including, among others: (1) substantial doubt about our ability to continue as a going concern, which has not been alleviated, and the risk that our plans intended to alleviate that substantial doubt will not be effectively implemented within one year after the date the financial statements are issued or, when implemented, will not mitigate the conditions and events that raise substantial doubt; (2) the effect of the substantial doubt about our ability to continue as a going concern on our relationships with customers, suppliers and channel partners, our ability to attract and retain qualified personnel and our ability to raise capital; (3) risk that we may not be able to accurately project and manage our growth and effectively execute our growth strategies or achieve profitability; (4) risk that we may be unable to meet our future capital requirements and we may require additional capital to support our business growth, and this capital might not be available on acceptable terms, or at all; (5) potential difficulties in maintaining manufacturing capacity and establishing expected mass manufacturing capacity in the future; (6) risks relating to issues or delays, disruptions and quality control problems in our manufacturing operations; (7) risks relating to being unable to control our manufacturing costs; (8) risks that we may be unable to meet our projected construction timelines, costs and production ramps, or we may experience difficulties in generating and maintaining demand for products manufactured there and related services; (9) restrictions in our existing and any future credit facilities, our ability to comply with financial covenants and the risk of cross-default, the risk that waivers or amendments may not be obtained from our lenders and the risk that our indebtedness may be accelerated or classified as current; (10) risks of operations in
The foregoing list of factors is not exhaustive and new factors may emerge from time to time that could also affect actual performance and results. For more information, please see the risk factors included in our Annual Report on Form 10-K for the year ended
Actual results, performance or achievements may differ materially, and potentially adversely, from any forward-looking statements and the assumptions on which those forward-looking statements are based. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as forward-looking statements are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control.
All information set forth herein speaks only as of the date hereof, and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date hereof except as may be required under applicable securities laws. Forecasts and estimates regarding our industry and end markets are based on sources we believe to be reliable, however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.
All references to the “Company,” “we,” “us,” or “our” refer to
Non-GAAP Financial Measures
To provide investors with additional information regarding our financial results,
Reconciliations to the most comparable GAAP measures, gross profit, gross margin, operating expenses, net profit/(loss), and net profit/(loss) per share, are contained in tabular form in the unaudited financial statements below. Non-GAAP adjusted gross profit is GAAP gross profit as adjusted for non-cash share-based compensation expense included in cost of revenues. Non-GAAP adjusted net profit/(loss) is GAAP net profit/(loss) as adjusted for non-cash share-based compensation expense and change in valuation of warrant liability and convertible loan. Non-GAAP adjusted net profit/(loss) per common share is GAAP net profit/(loss) per common share as adjusted for non-cash share-based compensation expense and change in valuation of warrant liability and convertible loan per common share. Non-GAAP EBITDA is defined as net profit/(loss) excluding depreciation and amortization, interest expense, interest income, and income tax expense or benefit. Non-GAAP adjusted EBITDA is defined as net profit/(loss) excluding depreciation and amortization, non-cash settled share-based compensation expense, interest expense, interest income, changes in fair value of our warrant liability and convertible loan and income tax expense or benefit. Non-GAAP adjusted operating expenses is defined as operating expenses excluding non-cash share-based compensation expense. Non-GAAP adjusted gross margin is defined as GAAP gross margin as adjusted for non-cash share-based compensation expense included in cost of revenues.
We use non-GAAP adjusted gross profit, non-GAAP EBITDA, non-GAAP adjusted EBITDA, non-GAAP adjusted operating expenses, non-GAAP adjusted net profit/(loss), non-GAAP adjusted net profit/(loss) per share and non-GAAP adjusted gross margin for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We consider them to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that these non-GAAP financial measures, when taken together with their most directly comparable GAAP measures provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our recurring core business operating results.
We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to our historical performance. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business. Accordingly, we believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and board of directors.
Non-GAAP financial measures have limitations as an analytical tool, and you should not consider them in isolation, or as a substitute for, financial information prepared in accordance with GAAP. For example, our calculation of non-GAAP adjusted EBITDA may differ from similarly titled non-GAAP measures, if any, reported by our peer companies, or our peer companies may use other measures to calculate their financial performance, and therefore our use of non-GAAP adjusted EBITDA may not be directly comparable to similarly titled measures of other companies. The principal limitation of non-GAAP adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recorded in our financial statements. In addition, it is subject to inherent limitations as it reflects the exercise of judgments by management about which expense and income are excluded or included in determining this non-GAAP financial measure. In order to compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. In addition, such financial information is unaudited and does not conform to SEC Regulation S-X and as a result, such information may be presented differently in our future filings with the
CONSOLIDATED BALANCE SHEETS (In thousands, except per share data, unaudited) |
|||||||
2026 |
2025 |
||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 127,828 | $ | 104,963 | |||
| Restricted cash | 15,257 | 64,275 | |||||
| Accounts receivable (net of allowance for credit losses of |
121,181 | 155,763 | |||||
| Notes receivable | 1,334 | 5,590 | |||||
| Inventories, net | 93,594 | 89,411 | |||||
| Prepaid expenses and other current assets | 15,727 | 17,221 | |||||
| Assets held for sale | — | 11,500 | |||||
| Total Current Assets | 374,921 | 448,723 | |||||
| Property, plant and equipment, net | 526,050 | 508,057 | |||||
| Land use rights, net | 11,771 | 11,570 | |||||
| Acquired intangible assets, net | 1,974 | 2,183 | |||||
| Operating lease right-of-use assets | 17,399 | 17,336 | |||||
| Deferred tax assets | 5,429 | 5,429 | |||||
| Other non-current assets | 14,649 | 12,150 | |||||
| Total Assets | $ | 952,193 | $ | 1,005,448 | |||
| Liabilities | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 62,639 | $ | 47,003 | |||
| Notes payable | 15,246 | 78,321 | |||||
| Advance from customers | 4,991 | 5,605 | |||||
| Accrued expenses and other current liabilities | 114,817 | 123,429 | |||||
| Amounts due to related parties | 181 | 2 | |||||
| Convertible loan measured at fair value | — | 140,929 | |||||
| Short-term bank borrowings | 104,179 | 93,052 | |||||
| Bonds payable | 41,693 | — | |||||
| Total Current Liabilities | 343,746 | 488,341 | |||||
| Long-term bonds payable | — | 41,693 | |||||
| Long-term bank borrowings | 14,443 | 13,227 | |||||
| Operating lease liabilities | 13,996 | 14,476 | |||||
| Other non-current liabilities | 36,914 | 37,198 | |||||
| Total Liabilities | $ | 409,099 | $ | 594,935 | |||
| Stockholders’ Equity | |||||||
| Common Stock ( |
$ | 39 | $ | 34 | |||
| Preferred Stock ( |
— | — | |||||
| Additional paid-in capital | 1,627,198 | 1,543,797 | |||||
| Statutory reserves | 6,032 | 6,032 | |||||
| Accumulated deficit | (1,085,953 | ) | (1,122,176 | ) | |||
| Accumulated other comprehensive loss | (4,222 | ) | (17,174 | ) | |||
| Total Equity | $ | 543,094 | $ | 410,513 | |||
| Total Liabilities and Equity | $ | 952,193 | $ | 1,005,448 | |||
CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data, unaudited) |
|||||||||||||||
| Three Months Ended |
Six Months Ended |
||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenues | $ | 87,262 | $ | 91,339 | $ | 147,874 | $ | 207,830 | |||||||
| Cost of revenues | (61,484 | ) | (59,616 | ) | (102,940 | ) | (133,091 | ) | |||||||
| Gross profit | 25,778 | 31,723 | 44,934 | 74,739 | |||||||||||
| Operating expenses: | |||||||||||||||
| General and administrative expenses | (13,886 | ) | (11,184 | ) | (26,827 | ) | (25,304 | ) | |||||||
| Research and development expenses | (8,860 | ) | (7,719 | ) | (17,670 | ) | (15,967 | ) | |||||||
| Selling and marketing expenses | (4,743 | ) | (3,424 | ) | (10,085 | ) | (10,223 | ) | |||||||
| Impairment loss of long-lived assets | (24 | ) | (1,364 | ) | (24 | ) | (1,364 | ) | |||||||
| Total operating expenses | (27,513 | ) | (23,691 | ) | (54,606 | ) | (52,858 | ) | |||||||
| Subsidy income | 15 | 995 | 18 | 2,411 | |||||||||||
| (Loss) profit from operations | (1,720 | ) | 9,027 | (9,654 | ) | 24,292 | |||||||||
| Other income and expenses: | |||||||||||||||
| Interest income | 733 | 198 | 1,115 | 375 | |||||||||||
| Interest expense | (1,328 | ) | (1,252 | ) | (2,555 | ) | (2,440 | ) | |||||||
| Changes in fair value of warrant liability and convertible loan | (5,837 | ) | (121,521 | ) | 58,001 | (78,361 | ) | ||||||||
| Foreign exchange (loss) gain | (4,705 | ) | 7,187 | (11,605 | ) | 10,854 | |||||||||
| Other income, net | 869 | 523 | 921 | 1,232 | |||||||||||
| (Loss) profit before provision for income taxes | (11,988 | ) | (105,838 | ) | 36,223 | (44,048 | ) | ||||||||
| Income tax expense | — | (220 | ) | — | (220 | ) | |||||||||
| Net (loss) profit | $ | (11,988 | ) | $ | (106,058 | ) | $ | 36,223 | $ | (44,268 | ) | ||||
| Net (loss) profit per share - Basic | $ | (0.03 | ) | $ | (0.33 | ) | $ | 0.11 | $ | (0.14 | ) | ||||
| Net loss per share - Diluted | $ | (0.03 | ) | $ | (0.33 | ) | $ | (0.06 | ) | $ | (0.14 | ) | |||
| Weighted average shares outstanding - Basic | 348,949 | 323,643 | 340,726 | 323,538 | |||||||||||
| Weighted average shares outstanding - Diluted | 348,949 | 323,643 | 382,948 | 323,538 | |||||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands, unaudited) |
|||||||
| Six Months Ended |
|||||||
| 2026 | 2025 | ||||||
| Cash flows from operating activities | |||||||
| Net profit (loss) | $ | 36,223 | $ | (44,268 | ) | ||
| Adjustments to reconcile net profit (loss) to net cash used in operating activities: | |||||||
| Depreciation of property, plant and equipment | 16,161 | 16,091 | |||||
| Noncash lease expenses | 1,418 | 1,311 | |||||
| Share-based compensation | 1,850 | 1,549 | |||||
| Changes in fair value of warrant liability and convertible loan | (58,001 | ) | 78,361 | ||||
| (Reversal) provision of credit losses | (873 | ) | 2,191 | ||||
| Impairment loss of long-lived assets | 24 | 1,364 | |||||
| Product warranty | 5,982 | 8,512 | |||||
| Other, net | 1,470 | (261 | ) | ||||
| Changes in operating assets and liabilities: | |||||||
| Notes receivable | (2,934 | ) | (13,957 | ) | |||
| Accounts receivable | 37,127 | (513 | ) | ||||
| Inventories | (4,612 | ) | 7,051 | ||||
| Prepaid expenses and other current assets | 1,324 | 8,830 | |||||
| Amounts due from/to related parties | 178 | (5 | ) | ||||
| Other non-current assets | 2,315 | 312 | |||||
| Notes payable | (64,821 | ) | (8,801 | ) | |||
| Accounts payable | 14,203 | 6,264 | |||||
| Advance from customers | (793 | ) | (2,279 | ) | |||
| Accrued expenses and other liabilities | (17,153 | ) | (16,876 | ) | |||
| Operating lease liabilities | (1,265 | ) | (1,350 | ) | |||
| Other non-current liabilities | (1,132 | ) | 797 | ||||
| Net cash (used in) generated from operating activities | (33,309 | ) | 44,323 | ||||
| Cash flows from investing activities | |||||||
| Purchases of property, plant and equipment | (14,170 | ) | (5,207 | ) | |||
| Proceeds on disposal of property, plant and equipment | 10,864 | 129 | |||||
| Net cash used in investing activities | (3,306 | ) | (5,078 | ) | |||
| Cash flows from financing activities | |||||||
| Proceeds from bank borrowings | 69,356 | 59,571 | |||||
| Repayment of bank borrowings | (60,829 | ) | (56,184 | ) | |||
| Repayment of bonds payable | — | (1,375 | ) | ||||
| Proceeds from sale of common stocks | 1,350 | — | |||||
| Payment for equity issuance costs | (329 | ) | — | ||||
| Deferred payment related to purchases of property, plant and equipment | (1,368 | ) | (8,811 | ) | |||
| Net cash generated from (used in) financing activities | 8,180 | (6,799 | ) | ||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 2,282 | (3,227 | ) | ||||
| (Decrease) increase in cash, cash equivalents and restricted cash | (26,153 | ) | 29,219 | ||||
| Cash, cash equivalents and restricted cash at beginning of the period | 169,238 | 109,601 | |||||
| Cash, cash equivalents and restricted cash at end of the period | $ | 143,085 | $ | 138,820 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands, unaudited) |
|||||
| Six Months Ended |
|||||
| 2026 | 2025 | ||||
| Reconciliation to amounts on consolidated balance sheets | |||||
| Cash and cash equivalents | $ | 127,828 | $ | 99,721 | |
| Restricted cash | 15,257 | 39,099 | |||
| Total cash, cash equivalents and restricted cash | $ | 143,085 | $ | 138,820 | |
RECONCILIATION OF GROSS PROFIT TO ADJUSTED GROSS PROFIT (In thousands, except percentages, unaudited) |
|||||||||||||||
| Three Months Ended |
Six Months Ended |
||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenues | $ | 87,262 | $ | 91,339 | $ | 147,874 | $ | 207,830 | |||||||
| Cost of revenues | (61,484 | ) | (59,616 | ) | (102,940 | ) | (133,091 | ) | |||||||
| Gross profit (GAAP) | $ | 25,778 | $ | 31,723 | $ | 44,934 | $ | 74,739 | |||||||
| Gross margin | 29.5 | % | 34.7 | % | 30.4 | % | 36.0 | % | |||||||
| Non-cash settled share-based compensation (included in cost of revenues) | 31 | 62 | 72 | 124 | |||||||||||
| Adjusted gross profit (non-GAAP) | $ | 25,809 | $ | 31,785 | $ | 45,006 | $ | 74,863 | |||||||
| Adjusted gross margin (non-GAAP) | 29.6 | % | 34.8 | % | 30.4 | % | 36.0 | % | |||||||
RECONCILIATION OF OPERATING EXPENSES TO ADJUSTED OPERATING EXPENSES (In thousands, unaudited) |
|||||||||||||||
| Three Months Ended |
Six Months Ended |
||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| General and administrative expenses | $ | (13,886 | ) | $ | (11,184 | ) | $ | (26,827 | ) | $ | (25,304 | ) | |||
| Research and development expenses | (8,860 | ) | (7,719 | ) | (17,670 | ) | (15,967 | ) | |||||||
| Selling and marketing expenses | (4,743 | ) | (3,424 | ) | (10,085 | ) | (10,223 | ) | |||||||
| Impairment loss of long-lived assets | (24 | ) | (1,364 | ) | (24 | ) | (1,364 | ) | |||||||
| Operating expenses (GAAP) | $ | (27,513 | ) | $ | (23,691 | ) | $ | (54,606 | ) | $ | (52,858 | ) | |||
| Non-cash settled share-based compensation (included in operating expenses) | 811 | 784 | 1,778 | 1,425 | |||||||||||
| Adjusted operating expenses (non-GAAP) | $ | (26,702 | ) | $ | (22,907 | ) | $ | (52,828 | ) | $ | (51,433 | ) | |||
RECONCILIATION OF NET (LOSS) PROFIT TO ADJUSTED NET (LOSS) PROFIT (In thousands, except per share data, unaudited) |
|||||||||||||||
| Three Months Ended |
Six Months Ended |
||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net (loss) profit (GAAP) | $ | (11,988 | ) | $ | (106,058 | ) | $ | 36,223 | $ | (44,268 | ) | ||||
| Changes in fair value of warrant liability and convertible loan* | 5,837 | 121,521 | (58,001 | ) | 78,361 | ||||||||||
| Non-cash settled share-based compensation* | 842 | 846 | 1,850 | 1,549 | |||||||||||
| Adjusted net (loss) profit (non-GAAP) | $ | (5,309 | ) | $ | 16,309 | $ | (19,928 | ) | $ | 35,642 | |||||
*The tax effect of the adjustments was nil.
| Three Months Ended |
Six Months Ended |
||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net (loss) profit per common share-Basic (GAAP) | $ | (0.03 | ) | $ | (0.33 | ) | $ | 0.11 | $ | (0.14 | ) | ||||
| Changes in fair value of warrant liability and convertible loan per common share | 0.02 | 0.38 | (0.17 | ) | 0.24 | ||||||||||
| Non-cash settled share-based compensation per common share | — | — | — | 0.01 | |||||||||||
| Adjusted net (loss) profit per common share-Basic (non-GAAP) | $ | (0.01 | ) | $ | 0.05 | $ | (0.06 | ) | $ | 0.11 | |||||
RECONCILIATION OF NET (LOSS) PROFIT TO EBITDA AND ADJUSTED EBITDA (In thousands, unaudited) |
|||||||||||||||
| Three Months Ended |
Six Months Ended |
||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Net (loss) profit (GAAP) | $ | (11,988 | ) | $ | (106,058 | ) | $ | 36,223 | $ | (44,268 | ) | ||||
| Interest expense (income), net | 595 | 1,054 | 1,440 | 2,065 | |||||||||||
| Income tax expense | — | 220 | — | 220 | |||||||||||
| Depreciation and amortization | 8,279 | 8,298 | 16,559 | 16,475 | |||||||||||
| EBITDA (non-GAAP) | $ | (3,114 | ) | $ | (96,486 | ) | $ | 54,222 | $ | (25,508 | ) | ||||
| Changes in fair value of warrant liability and convertible loan | 5,837 | 121,521 | (58,001 | ) | 78,361 | ||||||||||
| Non-cash settled share-based compensation | 842 | 846 | 1,850 | 1,549 | |||||||||||
| Adjusted EBITDA (non-GAAP) | $ | 3,565 | $ | 25,881 | $ | (1,929 | ) | $ | 54,402 | ||||||
Source: Microvast Holdings, Inc.